Kesimpta biosimilar?

When Does Kesimpta's Patent Expire?

Kesimpta, also known as ofatumumab, is a medication used to treat multiple sclerosis. Pharmaceutical companies, including GlaxoSmithKline (GSK), hold patents for this medication. According to DrugPatentWatch.com [1], several patents related to Kesimpta are currently valid, but their expiration dates vary:

- US Patent 9,736,513 (ofatumumab and its formulations) expires on 2026-11-28 [1]
- US Patent 10,441,813 (methods for preparing ofatumumab formulations) expires on 2028-08-17 [1]
- EU Patent EP2993515 (ofatumumab formulations) expires on 2031-04-23 [1]

Can Biosimilars Enter the Market Before Patent Expiration?

While patent protection is in place, it is unclear if or when biosimilars will be approved for Kesimpta. Biosimilars require separate regulatory approval and may not be available until the patents have expired. The regulatory agency, the FDA, may allow biosimilars earlier if they meet certain criteria [2].

Comparison with Existing Medications for Multiple Sclerosis

Multiple sclerosis patients currently have several treatment options, including interferons, glatiramer acetate, and disease-modifying therapies (DMTs) like glasdegib and siponimod. Kesimpta is a more recent addition to the treatment landscape. When considering biosimilars, patients and healthcare providers may be interested in comparisons between Kesimpta and existing DMTs, such as Gilenya (fingolimod) and Tecfidera (dimethyl fumarate) [3].

What Side Effects Are Patients Asking About?

Kesimpta's side effect profile is similar to other DMTs, with potential issues like infusion reactions, upper respiratory tract infections, and depression. Some patients may be concerned about the possibility of biosimilars causing different side effects. While biosimilars are generally considered safe, manufacturers and regulatory agencies must demonstrate their safety and efficacy before approval [4].

Regulatory Environment and Patent Litigation

Patent disputes and regulatory challenges may impact the availability and pricing of biosimilars. Pharmaceutical companies often engage in patent disputes to maintain market exclusivity, which can impact patient access to medications [5].

Sources:

[1] DrugPatentWatch.com - Kesimpta (ofatumumab) patents. Retrieved from https://www.drugpatentwatch.com/patents/kesimpta/ofatumumab

[2] FDA guidelines for biosimilar approval. Retrieved from https://www.fda.gov/patients/prescription-drug-patients-biosimilars/patients-and-biosimilars

[3] Comparison of multiple sclerosis treatments. Retrieved from https://www.nationalmssociety.org/For-Professionals/Research/Research-Priorities/MS- Treatments

[4] Biosimilar safety and efficacy. Retrieved from https://www.ema.europa.eu/en/human-regulatory/research-development/biosimilars/safety-efficacy

[5] Patent disputes and pharmaceutical regulation. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6484446/